Nanopublication

< Home

ID

http://purl.org/np/RAlMbRF28zz4RwDaPXAOxzVHJGUsd8gbQsbNWB05mXOWY

Formats

.trig | .trig.txt | .jelly | .jelly.txt

Content

@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RAlMbRF28zz4RwDaPXAOxzVHJGUsd8gbQsbNWB05mXOWY> .
@prefix sub: <http://purl.org/np/RAlMbRF28zz4RwDaPXAOxzVHJGUsd8gbQsbNWB05mXOWY#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_4450> bl:category bl:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_4450>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00398>;
    rdfs:label "nexavar is a kinase inhibitor indicated for the treatment of 1 1 1 2 1 3 nexavar r nexavar is indicated for the treatment of patients with advanced renal cell carcinoma rcc nexavar is indicated for the treatment of patients with locally recurrent or metastatic progressive differentiated thyroid carcinoma dtc that is refractory to radioactive iodine treatment";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB00398> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "B2ez15TlBiRJGlCA1gUAOoJSnFQi5T4PWCgEO/7LEbj0s36h40JP63/O3Abn9nPciVJtNCf8uJrNjp3ETcZSAPssy70yZ05VYg507t6dmgd760dq8A9SrsaPtJKTCUkPeKesUqPJlJyjxKnDI8B10LpxxnOs8ZNA2oYKTpBS+gA=";
    npx:hasSignatureTarget this: .
  
  this: dc1:created "2021-06-12T15:49:38.945+02:00"^^xsd:dateTime;
    dc1:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}